

OPHTOCYCLINE®


Chlortetracycline Hydrochloride 10 mg/g ophthalmic ointment

For dogs, cats and horses



For the treatment of keratitis, conjunctivitis and blepharitis caused by *Staphylococcus spp.*, *Streptococcus spp.*, *Proteus spp.*, and/or *Pseudomonas spp.* sensitive to chlortetracycline.

- Ophtocycline® is a broad spectrum ophthalmic antibiotic ointment in a paraffin base
- The active ingredient, chlortetracycline hydrochloride, has a broad spectrum of activity against both aerobic and anaerobic Gram-positive and Gram-negative bacteria
- Chlortetracycline is a bacteriostatic antibiotic which interferes with bacterial protein synthesis in the rapidly growing and reproducing bacterial cell and has both time-dependent and concentration dependent effects
- Licensed for use in dogs, cats and horses



OPHTOCYCLINE®

Chlortetracycline Hydrochloride 10 mg/g ophthalmic ointment

Dosage:

Horses: apply 2-3 cm of ointment (depending on the size of the animal) into the conjunctival sac 4 times per day for 5 days.

Dogs and Cats: Apply 0.5-2 cm of ointment (depending on the size of the animal) into the conjunctival sac 4 times per day for 5 days.

If after 3 days of treatment no clinical improvement has occurred, alternative therapy should be considered

Withdrawal Period:

Meat and offal: 1 day.

Ophtocycline® should not be used in horses producing milk intended for human consumption.

Ophtocycline

1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Ophtocycline 10 mg/g eye ointment for dogs, cats and horses (AT, BE, BG, CY, CZ, EL, ES, HR, HU, IE, IT, LU, NL, PT, RO, SI, SK, UK)
Ophtacin vet 10 mg/g eye ointment for dogs, cats and horses (DK, EE, FI, LT, LV, IS, NO, PL, SE)
Ophtocycline eye ointment for dogs, cats and horses (FR)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
1 gram contains: Active substances: Chlortetracycline hydrochloride 10.0 mg (equivalent to 9.3 mg chlortetracycline)
Excipient(s): For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM
Eye ointment. Yellowish to yellow homogenous ointment

4. CLINICAL PARTICULARS

- 4.1 Target species: Dogs, cats and horses.
- 4.2 Indications for use, specifying the target species:
Treatment of keratitis, conjunctivitis and blepharitis caused by *Staphylococcus* spp., *Streptococcus* spp., *Proteus* spp. and/or *Pseudomonas* spp. sensitive to chlortetracycline.
- 4.3 Contraindications: Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
- 4.4 Special warnings for each target species: None.
- 4.5 Special precautions for use: Special precautions for use in animals: Due to the likely variability (time, geographical) in the occurrence of tetracycline resistant bacteria, bacteriological sampling and susceptibility testing are recommended. Official, national and regional antimicrobial policies should be taken into account when the veterinary medicinal product is used. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to chlortetracycline and may decrease the effectiveness of treatment with other tetracyclines due to the potential for cross-resistance.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Due to possible sensitisation and/or hypersensitivity reactions direct skin contact should be avoided during administration. Wear impermeable gloves when handling the product.

In case of contact with the skin, wash exposed skin with water and soap. If you develop symptoms following exposure such as a skin rash, seek medical advice immediately and show the package leaflet or label to the physician.

- 4.6 Adverse reactions (frequency and seriousness): None known.
 - 4.7 Use during pregnancy and lactation: The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Use only according to the benefit/risk assessment by the responsible veterinarian.
 - 4.8 Interaction with other medicinal products and other forms of interaction: No data available.
 - 4.9 Amounts to be administered and administration route: For ocular use only. Horses: Apply 2-3 cm of ointment (depending on the size of the animal) in the conjunctival sac 4 times a day for 5 days. If after 3 days of treatment no clinical improvement has occurred, alternative therapy should be considered. Dogs and cats: Apply 0.5-2 cm of ointment (depending on the size of the animal) in the conjunctival sac 4 times a day for 5 days. If after 3 days of treatment no clinical improvement has occurred, alternative therapy should be considered.
 - 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary: No data available.
 - 4.11 Withdrawal period(s): Meat and offal: 1 day
Not authorised for use in horses producing milk intended for human consumption.
5. PHARMACOLOGICAL PROPERTIES
Pharmacotherapeutic group: ophthalmologicals: antibiotics
ATCvet code: QS01AA02
 - 5.1 Pharmacodynamic properties: Chlortetracycline

hydrochloride is a first-generation tetracycline. It is a predominantly bacteriostatic antibiotic that inhibits bacterial protein synthesis by binding to the 30S subunit of the bacterial ribosome. Chlortetracycline has time-dependent as well as concentration-dependent effects with AUC/MIC being the main PK/PD parameter. Chlortetracycline has a broad spectrum including both aerobic and anaerobic Gram-positive and Gram-negative bacteria. Resistance may be mediated by efflux, ribosomal protection and ribosomal modification. Cross-resistance among tetracyclines is common.

- 5.2 Pharmacokinetic particulars: Chlortetracycline is a non-lipophilic molecule. After topical administration in the eye, systemic absorption is expected to be minimal.

6. PHARMACEUTICAL PARTICULARS

- 6.1 List of excipients: Paraffin, light liquid, Wool fat. Paraffin, white soft
 - 6.2 Major incompatibilities: Not applicable
 - 6.3 Shelf life: Shelf-life of the veterinary medicinal product as packaged for sale: 24 months. Shelf-life after first opening the tube: 14 days
 - 6.4 Special precautions for storage: Do not store above 25°C.
 - 6.5 Nature and composition of immediate packaging: Epoxy resin lacquered aluminium tube with a content of 5 g, with a HDPE cannula and screw cap. One tube in a cardboard box.
 - 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products: Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
7. MARKETING AUTHORISATION HOLDER
Le Vet Beheer B.V. Wilgenweg 7, 3421 TV Oudewater, The Netherlands
 8. MARKETING AUTHORISATION NUMBER
Vm 41821/4043

Ophtocycline contains chlortetracycline hydrochloride UK: **POM-V** IE: **POM**

For further information contact: Dechra Veterinary Products Limited, Sansaw Business Park, Hadnall, Shrewsbury, Shropshire SY4 4AS
T +44 (0)1939 211200 F +44 (0)1939 211201 www.dechra.co.uk www.dechra.ie

Registered Office: 24 Cheshire Avenue, Cheshire Business Park, Lostock Gralam, Northwich CW9 7UA. Registered in England and Wales, Company Registration No. 5385888. Dechra Veterinary Products Limited is a trading business of Dechra Pharmaceuticals PLC.

Use medicines responsibly: www.noah.co.uk/responsible